Study MPX111381: A Dose-ranging Study Evaluating the Efficacy, Safety and Tolerability of GSK1838262 (XP13512) in the Prophylactic Treatment of Migraine Headache.

Trial Profile

Study MPX111381: A Dose-ranging Study Evaluating the Efficacy, Safety and Tolerability of GSK1838262 (XP13512) in the Prophylactic Treatment of Migraine Headache.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2013

At a glance

  • Drugs Gabapentin enacarbil (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors XenoPort
  • Most Recent Events

    • 19 Nov 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
    • 19 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Jul 2010 Primary endpoint 'Days with headache' has not been met according to media release from XenoPort and GlaxoSmithKline.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top